MARFEM 28 TABLET

국가: 캐나다

언어: 영어

출처: Health Canada

유효 성분:

DESOGESTREL; ETHINYL ESTRADIOL

제공처:

NOVOPHARM LIMITED

ATC 코드:

G03AA09

INN (국제 이름):

DESOGESTREL AND ESTROGEN

복용량:

0.15MG; 0.03MG

약제 형태:

TABLET

구성:

DESOGESTREL 0.15MG; ETHINYL ESTRADIOL 0.03MG

관리 경로:

ORAL

패키지 단위:

28

처방전 유형:

Prescription

치료 영역:

CONTRACEPTIVES

제품 요약:

Active ingredient group (AIG) number: 0224591001; AHFS:

승인 상태:

CANCELLED PRE MARKET

승인 날짜:

2015-10-16

제품 특성 요약

1
PRODUCT MONOGRAPH
PR
MARFEM
21
PR
MARFEM
28
desogestrel and ethinyl estradiol tablets, Novopharm Standard, 0.150
mg/0.030 mg
Oral Contraceptive
Novopharm Limited
30 Novopharm Court
Toronto, Ontario
M1B 2K9
Submission Control No: 118484
Date of Preparation:
July 6, 2009
Date of Revision:
2
TABLE OF CONTENTS
PART I: HEALTH PROFESSIONAL
INFORMATION........................................................ 3
SUMMARY PRODUCT INFORMATION
.......................................................................
3
INDICATIONS AND CLINICAL
USE.............................................................................
3
CONTRAINDICATIONS
..................................................................................................
3
WARNINGS AND
PRECAUTIONS.................................................................................
4
ADVERSE
REACTIONS.................................................................................................
11
DRUG INTERACTIONS
.................................................................................................
15
DOSAGE AND
ADMINISTRATION.............................................................................
20
OVERDOSAGE
...............................................................................................................
23
ACTION AND CLINICAL PHARMACOLOGY
........................................................... 23
STORAGE AND
STABILITY.........................................................................................
26
SPECIAL HANDLING INSTRUCTIONS
......................................................................
26
DOSAGE FORMS, COMPOSITION AND PACKAGING
............................................ 26
PART II: SCIENTIFIC INFORMATION
..............................................................................
27
PHARMACEUTICAL
INFORMATION.........................................................................
27
PART II: SCIENTIFIC INFORMATION
..............................................................................
28
P